Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 6/20 | 0.39 |
| ▸ | FDPS | P14324 | 5/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 3/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14199555 | 0.91 | GGPS1 (0.37) | GGPS1FDPSSRC | |
| Hydrochloric Acid SCHEMBL5671113 | 0.76 | GGPS1 (0.40) | GGPS1FDPSCA12MMP2CA9 | |
| Hydrochloric Acid SCHEMBL5672483 | 0.70 | FDPS (0.46) | GGPS1FDPS | |
| SCHEMBL12060627 | 0.68 | GGPS1 (0.56) | GGPS1FDPSCA12MMP2CA9 | |
| SCHEMBL12257829 | 0.67 | GGPS1 (0.54) | GGPS1FDPS | |
| SCHEMBL21856613 | 0.65 | — | — | |
| SCHEMBL12060611 | 0.64 | GGPS1 (0.51) | GGPS1 | |
| SCHEMBL12060607 | 0.64 | GGPS1 (0.51) | GGPS1FDPSLAP3ANPEP | |
| SCHEMBL12060601 | 0.63 | GGPS1 (0.83) | GGPS1FDPSCA12MMP2CA9 | |
| SCHEMBL12060623 | 0.63 | GGPS1 (0.56) | GGPS1FDPSCA12MMP2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071573-B2 | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100316676-A1 | Bisphosphonate Compounds and Methods for Bone Resorption Diseases, Cancer, Bone Pain, Immune Disorders, and Infectious Diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS | 2010-12-16 | — | — | US | disclosed |
| US-7745422-B2 | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080318906-A1 | BISPHOSPHONATE COMPOUNDS AND METHODS FOR BONE RESORPTION DISEASES, CANCER, BONE PAIN, IMMUNE DISORDERS, AND INFECTIOUS DISEASES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316676-A1 | Bisphosphonate Compounds and Methods for Bone Resorption Diseases, Cancer, Bone Pain, Immune Disorders, and Infectious Diseases | FDPS, GGPS1, MVD | GGPS1 2/4885FDPS 1/4885CA12 4602/4885 |
| US-20080318906-A1 | BISPHOSPHONATE COMPOUNDS AND METHODS FOR BONE RESORPTION DISEASES, CANCER, BONE PAIN, IMMUNE DISORDERS, AND INFECTIOUS DISEASES | FDPS, GGPS1, MVD | GGPS1 2/4885FDPS 1/4885CA12 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.